Voyager Therapeutics (FRA:VT6) 3-Year Revenue Growth Rate : 7.00% (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Voyager Therapeutics 3-Year Revenue Growth Rate?

Voyager Therapeutics's Revenue per Share for the three months ended in Mar. 2024 was €0.31.

During the past 12 months, Voyager Therapeutics's average Revenue per Share Growth Rate was -48.90% per year. During the past 3 years, the average Revenue per Share Growth Rate was 7.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was 38.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 11 years, the highest 3-Year average Revenue per Share Growth Rate of Voyager Therapeutics was 129.70% per year. The lowest was -61.40% per year. And the median was 34.00% per year.

Competitive Comparison of Voyager Therapeutics's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Voyager Therapeutics's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Voyager Therapeutics's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Voyager Therapeutics's 3-Year Revenue Growth Rate falls into.

Voyager Therapeutics 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Voyager Therapeutics (FRA:VT6) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Voyager Therapeutics 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Voyager Therapeutics's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Voyager Therapeutics (FRA:VT6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Voyager Therapeutics Inc (FRA:VT6) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

VYGR:USA VT6:Germany

Address

64 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.voyagertherapeutics.com

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. The company operates in a single segment of developing and commercializing gene therapies.

Voyager Therapeutics (FRA:VT6) Headlines

No Headlines